GleamWall
中文EN

MESO MESOBLAST LTD IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1345099 · Fiscal year ends 06/30

Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY191.4%
TTM net income YoY-16.1%
TTM EPS YoY5.1%
Revenue 3-yr CAGR19.0%
Net income 3-yr CAGR—

Margins

Gross margin70.2%
Operating margin—
Net margin-593.9%
FCF margin-294.4%
EBITDA margin—

Returns

ROE-19.0%
ROA-14.1%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets23.9%
Debt / equity0.20x
Current ratio1.99x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.49x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue4.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2023Q4*2023-06-302023Q32023-03-312023Q22022-12-312023Q12022-09-302022Q4*2022-06-302022Q32022-03-312022Q22021-12-312022Q12021-09-30
Income statement
Revenue$2.14M$1.94M$2.13M$1.50M$2.22M$2.01M$2.38M$3.59M
R&D expense$6.69M$7.07M$7.68M$5.74M$5.04M$8.25M$10.20M$9.33M
Interest expense$5.09M$4.90M$4.90M$4.55M$4.41M$4.30M$4.06M$4.14M
Pretax income-$21.96M-$18.65M-$24.56M-$16.94M-$21.51M-$21.35M-$26.02M-$22.71M
Income tax-$40,000-$46,000-$71,000-$55,000-$52,000-$45,000-$80,000-$62,000
Net income-$21.92M-$18.60M-$24.49M-$16.88M-$21.45M-$21.30M-$25.95M-$22.64M
EPS (basic)—-0.03-0.03-0.02—-0.03-0.04-0.03
EPS (diluted)—-0.03-0.03-0.02—-0.03-0.04-0.03
Weighted avg. shares (diluted)—736.58M736.58M696.07M—649.56M648.10M648.05M
Balance sheet
Cash & equivalents$71.32M$48.80M$67.62M$85.50M$60.45M$76.76M$94.85M$115.96M
Receivables$7.00M$8.39M$5.12M$3.86M$4.40M$5.63M$6.05M$5.63M
Current assets$81.66M$61.37M$78.13M$92.96M$69.84M$88.13M$108.80M$126.22M
PP&E, netmay include right-of-use assets (IFRS)$1.36M$1.48M$1.56M$1.79M$2.04M$2.24M$2.47M$2.75M
Total assets$669.41M$650.44M$668.06M$684.50M$662.14M$681.69M$704.44M$721.82M
Current liabilities$41.98M$53.92M$54.58M$48.80M$51.37M$52.19M$57.95M$92.90M
Short-term debt$5.95M$7.31M$5.94M$5.49M$5.02M$5.52M$5.20M$53.85M
Long-term debt$102.81M$99.04M$96.98M$94.19M$91.62M$88.65M$86.54M$42.65M
Total debt$108.76M$106.36M$102.92M$99.67M$96.63M$94.17M$91.75M$96.50M
Total liabilities$167.58M$168.27M$168.06M$161.69M$165.10M$164.56M$168.93M$162.07M
Shareholders' equity$501.84M$482.17M$500.00M$522.81M$497.04M$517.13M$535.51M$559.75M
Net debt$37.45M$57.56M$35.30M$14.17M$36.19M$17.41M-$3.10M-$19.46M
Cash flow statement
Operating cash flow-$16.28M-$16.25M-$16.45M-$14.29M-$13.89M-$15.47M-$16.81M-$18.20M
Investing cash flow$16,000$27,000-$34,000-$203,000-$47,000-$56,000-$30,000-$99,000
Financing cash flow$38.76M-$2.54M-$2.01M$40.30M-$2.22M-$2.57M-$4.34M-$2.15M
Depreciation & amortization$927,000$990,000$1.08M$1.10M$1.07M$1.11M$1.10M$1.09M
Stock-based compensation$1.11M$791,000$1.41M$350,000$1.09M$1.89M$1.48M$1.08M

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.